197 related articles for article (PubMed ID: 36478506)
1. Contemplating IL-6, a double-edged sword cytokine: Which side to use for stroke pathology?
Monsour M; Croci DM; Agazzi S; Borlongan CV
CNS Neurosci Ther; 2023 Feb; 29(2):493-497. PubMed ID: 36478506
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 6 trans-signalling and risk of future cardiovascular events.
Ziegler L; Gajulapuri A; Frumento P; Bonomi A; Wallén H; de Faire U; Rose-John S; Gigante B
Cardiovasc Res; 2019 Jan; 115(1):213-221. PubMed ID: 30052808
[TBL] [Abstract][Full Text] [Related]
3. Expression of Interleukin 6 signaling receptors in carotid atherosclerosis.
Ziegler L; Lundqvist J; Dreij K; Wallén H; de Faire U; Paulsson-Berne G; Hedin U; Matic L; Gigante B
Vasc Med; 2021 Feb; 26(1):3-10. PubMed ID: 33350884
[TBL] [Abstract][Full Text] [Related]
4. Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain.
Campbell IL; Erta M; Lim SL; Frausto R; May U; Rose-John S; Scheller J; Hidalgo J
J Neurosci; 2014 Feb; 34(7):2503-13. PubMed ID: 24523541
[TBL] [Abstract][Full Text] [Related]
5. Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling.
Wolf J; Waetzig GH; Chalaris A; Reinheimer TM; Wege H; Rose-John S; Garbers C
J Biol Chem; 2016 Jul; 291(31):16186-96. PubMed ID: 27226573
[TBL] [Abstract][Full Text] [Related]
6. IL6 trans-signaling associates with ischemic stroke but not with atrial fibrillation.
Ziegler L; Wallén H; Aspberg S; de Faire U; Gigante B
BMC Neurol; 2021 Aug; 21(1):306. PubMed ID: 34372806
[TBL] [Abstract][Full Text] [Related]
7. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
[TBL] [Abstract][Full Text] [Related]
8. Identification of IL-6 Signalling Components as Predictors of Severity and Outcome in COVID-19.
Rodríguez-Hernández MÁ; Carneros D; Núñez-Núñez M; Coca R; Baena R; López-Ruiz GM; Cano-Serrano ME; Martínez-Tellería A; Fuentes-López A; Praena-Fernandez JM; Garbers C; Hernández-Quero J; García F; Rose-John S; Bustos M
Front Immunol; 2022; 13():891456. PubMed ID: 35634332
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 and its receptors: a highly regulated and dynamic system.
Wolf J; Rose-John S; Garbers C
Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of interleukin-6 trans-signaling in the brain facilitates recovery from lipopolysaccharide-induced sickness behavior.
Burton MD; Sparkman NL; Johnson RW
J Neuroinflammation; 2011 May; 8():54. PubMed ID: 21595956
[TBL] [Abstract][Full Text] [Related]
11. Alternative intronic polyadenylation generates the interleukin-6 trans-signaling inhibitor sgp130-E10.
Sommer J; Garbers C; Wolf J; Trad A; Moll JM; Sack M; Fischer R; Grötzinger J; Waetzig GH; Floss DM; Scheller J
J Biol Chem; 2014 Aug; 289(32):22140-50. PubMed ID: 24973212
[TBL] [Abstract][Full Text] [Related]
12. The role of interleukin-6 signaling in nervous tissue.
Rothaug M; Becker-Pauly C; Rose-John S
Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1218-27. PubMed ID: 27016501
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor.
Garbers C; Thaiss W; Jones GW; Waetzig GH; Lorenzen I; Guilhot F; Lissilaa R; Ferlin WG; Grötzinger J; Jones SA; Rose-John S; Scheller J
J Biol Chem; 2011 Dec; 286(50):42959-70. PubMed ID: 21990364
[TBL] [Abstract][Full Text] [Related]
14. Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production.
Ahmed S; Marotte H; Kwan K; Ruth JH; Campbell PL; Rabquer BJ; Pakozdi A; Koch AE
Proc Natl Acad Sci U S A; 2008 Sep; 105(38):14692-7. PubMed ID: 18796608
[TBL] [Abstract][Full Text] [Related]
15. Altered interleukin-6 receptor, IL-6R and gp130, production and expression and decreased SOCS-3 expression in placentas from women with pre-eclampsia.
Zhao S; Gu Y; Dong Q; Fan R; Wang Y
Placenta; 2008 Dec; 29(12):1024-8. PubMed ID: 18986700
[TBL] [Abstract][Full Text] [Related]
16. Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses.
Lamertz L; Rummel F; Polz R; Baran P; Hansen S; Waetzig GH; Moll JM; Floss DM; Scheller J
Sci Signal; 2018 Oct; 11(550):. PubMed ID: 30279168
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 trans-signaling in the senescent mouse brain is involved in infection-related deficits in contextual fear conditioning.
Burton MD; Johnson RW
Brain Behav Immun; 2012 Jul; 26(5):732-8. PubMed ID: 22062497
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 "Trans-Signaling" and Ischemic Vascular Disease: The Important Role of Soluble gp130.
Morieri ML; Passaro A; Zuliani G
Mediators Inflamm; 2017; 2017():1396398. PubMed ID: 28250574
[TBL] [Abstract][Full Text] [Related]
19. Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor α to gp130 expression: fusing experimental insights and dynamic modelling.
Reeh H; Rudolph N; Billing U; Christen H; Streif S; Bullinger E; Schliemann-Bullinger M; Findeisen R; Schaper F; Huber HJ; Dittrich A
Cell Commun Signal; 2019 May; 17(1):46. PubMed ID: 31101051
[TBL] [Abstract][Full Text] [Related]
20. The N-terminus of gp130 is critical for the formation of the high-affinity interleukin-6 receptor complex.
Moritz RL; Ward LD; Tu GF; Fabri LJ; Ji H; Yasukawa K; Simpson RJ
Growth Factors; 1999; 16(4):265-78. PubMed ID: 10427501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
